Amneal's Narcolepsy Drug: A Shot in the Arm?

Amneal Pharmaceuticals stock jumps after FDA approves its generic narcolepsy drug, challenging a market dominated by Xyrem and offering a more affordable option to 150,000 Americans. This approval marks a major milestone for Amneal, driving stock gains and contributing to a strong year with significant long-term growth potential for investors. Hosted on Acast. See acast.com/privacy for more information.